About Ipsen
Ipsen is a publicly listed company based in Boulogne-billancourt (France) founded in 1929. Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes. The company has 5,360 employees. Ipsen has completed 9 acquisitions, including Albireo Pharma, Canbex Therapeutics and Clementia. Its website ipsen.com draws about 113 thousand monthly visits. Ipsen offers products and services including Oncology Medicines, Rare Disease Treatments, and Neuroscience Products. Its focus areas include Biopharma Outsourcing, Diversified, Diversified Pharmaceuticals and Drugs. Its legal entity is Ipsen Pharma.
Company details
Ipsen is a mid-sized biopharmaceutical company focused on innovation and specialty care to improve patient health outcomes. The company develops and commercializes transformative medicines in oncology, rare disease, and neuroscience. With a commitment to precision focus on RD, Ipsen builds a pipeline at every stage from discovery to late-stage clinical development.
- Annual Revenue$4.32 B (USD)8.1as on Dec 31, 2025
- Net Profit$521.11 M (USD)28.22as on Dec 31, 2025
- EBITDA$1.29 B (USD)6.4as on Dec 31, 2025
- Latest Funding Round$617.66K (USD), Grant
Dec 2023
- InvestorsQualium Investissement
& 1 more
- Employee Count5,360
- Investments & AcquisitionsAlbireo Pharma
& 8 more
Products & Services of Ipsen
Ipsen offers a comprehensive portfolio of products and services, including Oncology Medicines, Rare Disease Treatments, and Neuroscience Products.
Treatments for cancers like neuroendocrine tumors
Drugs for rare conditions such as liver diseases
Medicines for debilitating neurological conditions
Apps and channels of Ipsen
its YouTube channel Ipsen has 1.05K subscribers and 30 videos.
Videos from Ipsen
The most watched videos on Ipsen's YouTube channel, Ipsen (1.05K subscribers). Click a video to play it here.
More on Ipsen.
Funding Insights of Ipsen
- Total Rounds 4
- Last Round Grant — $617,663
- Investors Count 2
All 4 funding rounds of Ipsen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $617,663 | Grant | – | – | |
| Apr 2021 | $947,920 | Grant | – | – | |
| Jun 2015 | $60M | Post-IPO | – | – | – |
| Jun 1998 | Private Equity Round | – | – |
2 investors in total: 2 institutional.
Investors in Ipsen
Ipsen has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Qualium Investissement and Ministry of Economy, Finance and Industrial and Digital Sovereignty.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on multiple sectors | 1998 | qualium-investissement.com | Paris, France | |
| economie.gouv.fr |
Investor details for Ipsen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ipsen
738 people are tracked at Ipsen (380 in leadership, 13 in board & advisors, 345 in team); the tracked headcount is 5,360.
| Name | Role | Group |
|---|---|---|
Aurélien Biechy | Senior Director IP | Leadership |
Dr Fiona Maxwell | Vice President, Head Of Early Stage Clinical Development | Leadership |
Luis Zuniga Dnp | Regional Field Medical Director | Leadership |
Yu Fu | Medical Information Director | Leadership |
David Loew | CEO | Leadership |
Torianio White | Director Medical Affairs Training | Leadership |
Caroline Boin-Margerit | VP Corporate Communications | Leadership |
David Gruber | Senior Director Of Bioprocess Development (usp & Dsp) | Leadership |
Helene. Mathiex-Fortunet | Vice President Drugdevelopment- Primary Careproducts | Leadership |
Karen Martin | Svp, Chief IP Counsel | Leadership |
Stéphane Masseran | SVP & Chief Procurement Officer; Head Of Global Real Estate | Leadership |
Vincent Berny | Head Of Global Product Quality | Leadership |
Jennifer Glennon | Senior Vice President, Global Portfolio Operations | Leadership |
Yacoub Adjibade | Vice President | Leadership |
Chris Watters | Ad Interim Senior Vice President, Franchise Head, Oncology Business Unit | Leadership |
Sarah O'Mahony | Global Head Of Asset Operations Neuroscience | Leadership |
Sarah Desi Arragon | Senior Director, Strategic Alliance Management | Leadership |
Josep Catllà | EVP & Chief Corporate Affairs Officer | Leadership |
Anne-Sophie Dubromer | Global Digital Transformation And Communication Director | Leadership |
Jean-Francois Muller | Vice President Procurement Americas | Leadership |
718 more people are available in the full profile.
Complete people profiles for Ipsen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ipsen
Ipsen is a publicly listed company on the EURONEXT with ticker symbol IPN in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date06 Dec 2005
- Listed onEuronext: IPN
- Listed entityIpsen SA
- Exchange sectorHealth technology
- ISINFR0010259150
- Share price143.10 EUR (+0.35% on the day) · 2026-10-14
- Market capitalisation11,794,368,042.00 EUR
- Price to earnings23.2
- EPS (diluted, trailing year)6.18 EUR
- Dividend yield1.12%
- Volume (last session)6,141
Financials of Ipsen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 3.68B EUR | 443.5M EUR | 1.10B EUR |
| 2024 | 3.40B EUR | 345.9M EUR | 1.04B EUR |
| 2023 | 3.13B EUR | 644.4M EUR | 945.5M EUR |
| 2022 | 3.02B EUR | 648.6M EUR | 1.13B EUR |
| 2021 | 2.64B EUR | 646.6M EUR | 1.11B EUR |
Detailed financial statements for Ipsen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ipsen
Ipsen has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include Albireo Pharma, Canbex Therapeutics and Clementia.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of antibodies for treating infectious diseases and cancer | memo-therapeutics.com | Schlieren, Switzerland | 2012 | Jul 2026 | $228.14M | |
Therapeutics for cancer treatment are developed by Kartos Therapeutics. | kartosthera.com | Redwood, United States | 2018 | Jun 2026 | •••• | |
ImCheck Therapeutics is focused on immune system modulation innovation. | imchecktherapeutics.com | Marseille, France | 2015 | Dec 2025 | •••• | |
Novel bile acid modulators are developed for gastrointestinal diseases. | albireopharma.com | Gothenburg, Sweden | 2008 | Jan 2023 | $952M | |
Small Molecule to treat rare bone diseases such as Fibrodysplasia Ossificans Progressiva (FOP). | clementiapharma.com | Dorval, Canada | 2012 | Feb 2019 | $1.3B | |
Information on liposome injections for pancreatic cancer is provided. | onivyde.com | Wrexham, United Kingdom | 2013 | Jan 2017 | •••• | |
Theranostic compounds are developed for diagnosing and treating neuroendocrine tumors. | octreopharmsciences.com | Berlin, Germany | 2009 | May 2015 | $56.96M | |
Small molecule drugs for spasticity in multiple sclerosis are developed. | canbex.co.uk | London, United Kingdom | 2005 | Feb 2015 | •••• | |
Bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. | syntaxin.com | Abingdon, United Kingdom | 2005 | Jul 2013 | $36.58M |
Complete acquisition details for Ipsen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Ipsen
13 dated milestones of Ipsen across 97 years, from founding to its latest funding, stage changes and deals.
- Founded Ipsen is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Syntaxin.
- Acquisition Acquires Canbex Therapeutics.
- Acquisition Acquires OctreoPharm Sciences.
- Acquisition Acquires ONIVYDE.
- Acquisition Acquires Clementia.
- Acquisition Acquires Albireo Pharma.
- Funding Latest funding round, Grant, of $618K.
- Acquisition Acquires ImCheck Therapeutics.
- Acquisition Acquires Kartos Therapeutics.
- Acquisition Acquires Memo Therapeutics.
Web traffic of Ipsen
The website of Ipsen (ipsen.com) receives about 112.9K visits a month and ranks #336,868 among all websites worldwide, #278 in Biotechnology and Pharmaceuticals.
- Monthly visits112.9K
▼ 9.6% vs previous month
- Unique visitors52.4K
per month
- Global rank#336,868
among all websites
- Category rank#278
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit2.0
- Average visit34 sec
- DevicesDesktop 27% · Mobile 73%
Websites whose visitors overlap most with Ipsen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| besins-healthcare.com | 100% | #1,121,648 | View details | ||
ipsenus.com | ipsenus.com | 97% | – | ||
| arkopharma.com | 92% | 220.4K | #215,630 | View details | |
| guerbet.com | 84% | 32.6K | #864,402 | View details | |
| tevapharm.com | 83% | 166.9K | #278,209 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Ipsen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ipsen
Complete news archive for Ipsen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ipsen
Ipsen was founded in 1929 and raised its 1st funding round 69 years after it was founded.
Ipsen is headquartered in Boulogne-billancourt, France. It is registered at Boulogne-billancourt, Hauts-de-seine, France.
Ipsen has 5,360 employees.
Annual revenue of Ipsen is $4.32B as on Dec 31, 2025.
Ipsen is a mid-sized biopharmaceutical company focused on innovation and specialty care to improve patient health outcomes. The company develops and commercializes transformative medicines in oncology, rare disease, and neuroscience. With a commitment to precision focus on RD, Ipsen builds a pipeline at every stage from discovery to late-stage clinical development.
Ipsen offers Oncology Medicines, Rare Disease Treatments, and Neuroscience Products.
Yes, Ipsen is publicly traded on EURONEXT under the ticker symbol IPN.
Ipsen has made 9 acquisitions, including Albireo Pharma, Canbex Therapeutics, and Clementia.
Ipsen has 2 investors. Key investors include Qualium Investissement, and Ministry of Economy, Finance and Industrial and Digital Sovereignty.
Ipsen operates through Ipsen Pharma.
The website of Ipsen receives about 113 thousand visits a month and ranks #336,868 among all websites worldwide.